Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022, page-5

We need to keep in mind that the MBC ph3 trial, when/if it starts, will take five or six years to complete, that's how long the ph2b took. If it starts next year then we are looking at 2028/29 with possible FDA approval in 2030. By then there will only be five years left on the patent. If we go it alone it will be a real drag on company resources for a long time. I'm not sure it offers any upside on the share price unless we find a deal and I doubt we will do it on our own. Just my opinion.

The fast track with Keytruda and NSCLC is more interesting for company valuation,imo. Also, hopefully next year we will start auto-immune, although I wouldn't hold my breath because this project is glacial, which should generate new interest in the stock.